Last reviewed · How we verify
Megestrol Acetate and olanzapine
This combination uses megestrol acetate (a progestin) to stimulate appetite and promote weight gain, while olanzapine (an atypical antipsychotic) provides additional appetite stimulation and may address underlying psychiatric or behavioral symptoms.
This combination uses megestrol acetate (a progestin) to stimulate appetite and promote weight gain, while olanzapine (an atypical antipsychotic) provides additional appetite stimulation and may address underlying psychiatric or behavioral symptoms. Used for Cancer cachexia and weight loss in advanced malignancy, Appetite stimulation and nutritional support in wasting syndromes.
At a glance
| Generic name | Megestrol Acetate and olanzapine |
|---|---|
| Sponsor | Qingdao Central Hospital |
| Drug class | Progestin + atypical antipsychotic combination |
| Target | Hypothalamic appetite centers (megestrol); dopamine D2 and serotonin 5-HT2A receptors (olanzapine) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Palliative Care / Cachexia |
| Phase | Phase 3 |
Mechanism of action
Megestrol acetate is a synthetic progestin that acts on the hypothalamus to increase appetite and caloric intake, commonly used in cachexia and wasting syndromes. Olanzapine is an atypical antipsychotic that antagonizes dopamine and serotonin receptors and has known side effects of appetite stimulation and weight gain. The combination leverages both agents' appetite-enhancing properties for synergistic benefit in conditions characterized by severe weight loss or nutritional decline.
Approved indications
- Cancer cachexia and weight loss in advanced malignancy
- Appetite stimulation and nutritional support in wasting syndromes
Common side effects
- Weight gain
- Sedation
- Hyperglycemia
- Thromboembolic events (megestrol)
- Metabolic syndrome
- Extrapyramidal symptoms (olanzapine)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Megestrol Acetate and olanzapine CI brief — competitive landscape report
- Megestrol Acetate and olanzapine updates RSS · CI watch RSS
- Qingdao Central Hospital portfolio CI